225 related articles for article (PubMed ID: 24510314)
1. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
Leyvraz S; Piperno-Neumann S; Suciu S; Baurain JF; Zdzienicki M; Testori A; Marshall E; Scheulen M; Jouary T; Negrier S; Vermorken JB; Kaempgen E; Durando X; Schadendorf D; Gurunath RK; Keilholz U
Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Voelter V; Schalenbourg A; Pampallona S; Peters S; Halkic N; Denys A; Goitein G; Zografos L; Leyvraz S
Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients.
Egerer G; Lehnert T; Max R; Naeher H; Keilholz U; Ho AD
Int J Clin Oncol; 2001 Feb; 6(1):25-8. PubMed ID: 11706523
[TBL] [Abstract][Full Text] [Related]
4. Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study.
Farolfi A; Ridolfi L; Guidoboni M; Milandri C; Calzolari F; Scarpi E; Amadori D; Ridolfi R
J Chemother; 2011 Oct; 23(5):300-5. PubMed ID: 22005064
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
Peters S; Voelter V; Zografos L; Pampallona S; Popescu R; Gillet M; Bosshard W; Fiorentini G; Lotem M; Weitzen R; Keilholz U; Humblet Y; Piperno-Neumann S; Stupp R; Leyvraz S
Ann Oncol; 2006 Apr; 17(4):578-83. PubMed ID: 16469752
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic uveal melanoma with intravenous fotemustine.
Spagnolo F; Grosso M; Picasso V; Tornari E; Pesce M; Queirolo P
Melanoma Res; 2013 Jun; 23(3):196-8. PubMed ID: 23624366
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy.
Leyvraz S; Spataro V; Bauer J; Pampallona S; Salmon R; Dorval T; Meuli R; Gillet M; Lejeune F; Zografos L
J Clin Oncol; 1997 Jul; 15(7):2589-95. PubMed ID: 9215829
[TBL] [Abstract][Full Text] [Related]
8. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
Khayat D; Cour V; Bizzari JP; Aigner K; Borel C; Cohen-Alloro G; Weil M; Auclerc G; Buthiau D; Bousquet JC
Am J Clin Oncol; 1991 Oct; 14(5):400-4. PubMed ID: 1951178
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
Schuster R; Lindner M; Wacker F; Krössin M; Bechrakis N; Foerster MH; Thiel E; Keilholz U; Schmittel A
Melanoma Res; 2010 Jun; 20(3):191-6. PubMed ID: 20335820
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
Siegel R; Hauschild A; Kettelhack C; Kähler KC; Bembenek A; Schlag PM
Eur J Surg Oncol; 2007 Jun; 33(5):627-32. PubMed ID: 17196362
[TBL] [Abstract][Full Text] [Related]
11. [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Cui CL; Chi ZH; Yuan XQ; Lian HY; Si L; Guo J
Ai Zheng; 2008 Aug; 27(8):845-50. PubMed ID: 18710619
[TBL] [Abstract][Full Text] [Related]
12. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
Becker JC; Terheyden P; Kämpgen E; Wagner S; Neumann C; Schadendorf D; Steinmann A; Wittenberg G; Lieb W; Bröcker EB
Br J Cancer; 2002 Oct; 87(8):840-5. PubMed ID: 12373596
[TBL] [Abstract][Full Text] [Related]
13. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
Fety R; Lucas C; Solere P; Cour V; Vignoud J
Cancer Chemother Pharmacol; 1992; 31(2):118-22. PubMed ID: 1451232
[TBL] [Abstract][Full Text] [Related]
14. Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Niederkorn A; Wackernagel W; Artl M; Schwantzer G; Aigner B; Richtig E
Acta Ophthalmol; 2014 Dec; 92(8):e696-7. PubMed ID: 24774993
[No Abstract] [Full Text] [Related]
15. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
16. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy.
Salmon RJ; Levy C; Plancher C; Dorval T; Desjardins L; Leyvraz S; Pouillart P; Schlienger P; Servois V; Asselain B
Eur J Surg Oncol; 1998 Apr; 24(2):127-30. PubMed ID: 9591028
[TBL] [Abstract][Full Text] [Related]
17. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Nguyen BB; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre J; de Gislain C; Bensadoun JR; Clavel M
Cancer Radiother; 2003 Feb; 7(1):1-8. PubMed ID: 12648711
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
19. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
20. Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion.
Ludwig JM; Haubold J; Bauer S; Richly H; Siveke JT; Wimmer J; Umutlu L; Schaarschmidt BM; Theysohn JM
Radiol Oncol; 2021 May; 55(3):347-353. PubMed ID: 34051707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
